Tamsulosin
- Atc Codes:G04CA02
- CAS Codes:106463-17-6#106133-20-4
- PHARMGKB ID:106463-17-6#106133-20-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Aglandin, Alna Retard, Stichtulosin, Tamsu, Tamsulijn Retard, Tamsulosin; Belgium: Omic, Ranomax, Tamsulosine; Bulgaria: Omnic, Tamsol, Tamsudil, Tanyz, Urimax; Cyprus: Omnictocas, Pamsvax; Czech Republic: Apo-Tamis, Damurgin, Fokusin, Lannatam, Omnic, Solesmin, Taflosin, Tamipro, Tamsec, Tamsulosin, Tamurox, Tanyz, Urostad; Denmark: Cepalux, Masulin, Omnic, Omnistad, Tamsin, Tamsukon, Tamsulogen, Tamsulosinhydrochlorid; Estonia: Flosin, Fokusin, Omipro, Omnic, Omsal, Tamsulosin, Tanyz, Urostad; Finland: Expros, Omnic, Tamictor, Tamsact, Tamsu-Anlini, Tamsucinfa, Tamsugaran, Tamsulogen, Tamsulosiinihydrokloridi, Tamsumin, Tamsupli; France: Josir, Mecir, Omexel, Omix, Tamsulosine; Germany: Alna, Mecir, Omnic, Prostacure, Prostadil, Prostalitan, Prostazid, Tadin, Tamsublock, Tamsulo-Isis, Tamsulosin, Tamsumedin, Tamsunar; Greece: Novelio, Omnic, Pradif, Prosolvin, Ranomax, Sintamel, Tamsol, Tamsolet, Tamsulijn, Tamsulosin, Zidrolin; Hungary: Flosin, Flowtam, Fokusin, Galebon, Omipro, Omnic, Omsal, Provosal, Proximic, Ranomax, Sulbedor, Tamsol, Tamsudil, Tamsugen, Tamsulonorm, Tamsulosin, Tamta, Tanyz, Totalprost, Tulosin, Urostad; Ireland: Omnexel, Omnic Hard, Omsil, Prolosin, Tacap, Tamnic, Tamsu, Tamsulas, Tamsulosin; Italy: Antunes, Botam, Lura, Omnic, Pradif, Probena, Tamlic, Tamsulosin, Tamsulosina; Latvia: Flosin, Fokusin, Omnic, Omsal, Tamipro, Tamosin, Tamsulosin, Tanyz, Urostad; Lithuania: Tamsulosin; Luxembourg: Omic; Malta: Omnic, Tamsulosin; Netherlands: Mapelor, Omnic, Tamsin, Tamsulijn, Tamsulosine, Tamsulosini; Poland: Apo-Tamis, Bazetham, Flosin, Fokusin, Omipro, Omnic, Omsal, Prostamnic, Proximic, Ranlosin, Symlosin, Tamik-Biofarm, Tamsec, Tamsudil, Tamsugen, Tamsulek, Tamsulosin, Tamzul, Tanyz, Uprox, Urostad, Wintamsu; Portugal: Omnic, Pradif, Tansulosina; Romania: Contiflo, Fokusin, Omnic, Taflosin, Tamsol, Tamsulosin, Tamsulosini, Tanyz; Slovakia: Bazetham, Damurgin, Flosin, Fokusin, Geroprostan, Omipro, Omnic, Tamsulosin, Tamurox, Tanyz, Urostad; Slovenia: Bazetham, Morvesin, Omnic, Taflosin, Tamsulozin, Tanyz; Spain: Manfredol, Omnic, Sebrane, Tamsulosina, Urolosin, Zuantrip; UK: Diffundox, Flomaxtra, Stronazon, Tabphyn, Tamsulosin.
North America
Canada: Flomax, Tamsulosin; USA: Flomax.
Latin America
Argentina: Aclosan, Biprokam, Espontal, Lostam, Omnic, Prostoklar, Reduprost-Raffo, Secotex, Tamsuna, Tansiloprost, Uroprost; Brazil: Contiflo, Omnic, Secotex, Tamsulon; Mexico: Amzuvag, Asoflon, Hipebe, Secadryckel, Secotex, Suprosina.
Asia
Japan: Halonerol, Halthrow, Haranasin, Harnal D, Hartam, Palnac, Restream, Tamslon, Urosulol.
Drug combinations
Tamsulosin and Dutasteride
Tamsulosin and Finasteride
Chemistry
Tamsulosin Hydrochloride: C~20~H~28~N~2~O~5~S.HCl. Mw: 444.97. (1) Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, monohydrochloride, (R)-; (2)(-)-(R)-5-[2-[[2-(o-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide monohydrochloride. CAS-106463-17-6; CAS-106133-20-4 (tamsulosin)(1993).
Pharmacologic Category
Sympatholytic (Adrenergic Blocking) Agents; Selective α-Adrenergic Blocking Agents. α~1~-Adrenergic blocker. (ATC-Code: G04CA02).
Mechanism of action
An antagonist of α~1A~-adrenoreceptors in prostate. Blocking them leads to relaxation of smooth muscle in bladder neck and prostate causing improvement of urine flow and decreased symptoms of benign prostatic hyperplasia.
Therapeutic use
Treatment of signs and symptoms of benign prostatic hyperplasia.
Pregnancy and lactiation implications
Not approved for use in women.
Unlabeled use
Symptomatic treatment of bladder outlet obstruction or dysfunction.
Contraindications
Hypersensitivity to tamsulosin or any component of the formulation.
Warnings and precautions
Discontinue if symptoms of angina occur or worsen. Intraoperative floppy iris syndrome observed in cataract surgery patients on, or previously treated with, α~1~-blockers (causality not established). May cause significant orthostatic hypotension and syncope, especially with first dose. Anticipate similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (e.g. sildenafil, tadalafil, vardenafil) is introduced. «First-dose» orthostatic hypotension may occur 4-8 hours after dosing. Priapism associated with use (rarely). Rarely, patients with sulfa allergy also developed allergic reaction to tamsulosin (avoid use when previous reaction severe). Not indicated for use in women or in children.